What is HC Wainwright’s Forecast for Assertio Q1 Earnings?

Assertio Holdings, Inc. (NASDAQ:ASRT) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Assertio in a report issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.19 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Assertio’s Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.51 EPS and FY2027 earnings at $1.11 EPS.

Assertio (NASDAQ:ASRT) last released its quarterly earnings data on Monday, March 16th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($3.05) by $1.19. The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $6.20 million. Assertio had a negative net margin of 25.59% and a negative return on equity of 30.26%.

Several other brokerages have also issued reports on ASRT. Zacks Research lowered shares of Assertio from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Wall Street Zen downgraded Assertio from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.00.

Assertio Stock Up 4.7%

Shares of NASDAQ:ASRT opened at $14.00 on Monday. The company has a 50 day moving average price of $11.95 and a two-hundred day moving average price of $11.81. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.51 and a current ratio of 1.70. The company has a market capitalization of $90.23 million, a PE ratio of -2.88 and a beta of 0.73. Assertio has a 52 week low of $7.65 and a 52 week high of $15.15.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ASRT. Virtu Financial LLC acquired a new position in shares of Assertio in the third quarter valued at approximately $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Assertio during the fourth quarter worth $41,000. Rothschild Wealth LLC bought a new stake in Assertio in the 4th quarter valued at $172,000. Perritt Capital Management Inc lifted its position in Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after acquiring an additional 119,281 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Assertio by 536.0% in the 3rd quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock worth $336,000 after purchasing an additional 321,584 shares during the period. Institutional investors own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.